Literature DB >> 862307

Absorption and metabolism of lanatoside C. II. Fate after oral administration.

S Aldous, R Thomas.   

Abstract

The absorption, metabolism, and excretion of lanatoside C were studied in hospitalized subjects following oral administration of the tritiated drug. Previous reports of an unusual double peak in plasma levels of radioactivity were confirmed. Fifty plasma samples taken from 31 patients showed that an average of 74% of the radioactive material was digoxin and its metabolites. There was little or no lanatoside C in 36 of the 50 samples of plasma. Similar results were obtained for urine radioactivity. The results confirm that lanatoside C is converted to "digoxin" in the gut prior to absorption as previously proposed by us. "Digoxin" refers to digoxin and its breakdown products, namely, digoxigenin and its mono- and didigitoxosides. According to these proposals, the conversion to "digoxin" takes place partly as a result of acid hydrolysis in the gut and partly by the action of bacteria in the intestine. The effects of concurrent administration of antacid therapy, anticholinergic therapy, and food on the fate of oral lanatoside C were separately studied. There were no significant differences between groups with respect to the amount of radioactive material absorbed or excreted, but there were marked qualitative differences in the plasma profiles. There was a statistically significant increase in the time to the first peak in plasma radioactivity in patients concurrently receiving either food or anticholinergic therapy and there was a significant decrease in the relative height of the first peak in patients treated concurrently with antacid.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 862307     DOI: 10.1002/cpt1977216647

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Expression of recombinant Digitalis lanata EHRH. cardenolide 16'-O-glucohydrolase in Cucumis sativus L. hairy roots.

Authors:  He-Ping Shi; Peter Lindemann
Journal:  Plant Cell Rep       Date:  2006-06-15       Impact factor: 4.570

2.  Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy.

Authors:  Jian Teng; Seyedali Hejazi; Christian E Badr; Bakhos A Tannous
Journal:  Stem Cells       Date:  2014-08       Impact factor: 6.277

3.  Cardiac glycosides target barrier inflammation of the vasculature, meninges and choroid plexus.

Authors:  Deidre Jansson; Victor Birger Dieriks; Justin Rustenhoven; Leon C D Smyth; Emma Scotter; Miranda Aalderink; Sheryl Feng; Rebecca Johnson; Patrick Schweder; Edward Mee; Peter Heppner; Clinton Turner; Maurice Curtis; Richard Faull; Mike Dragunow
Journal:  Commun Biol       Date:  2021-02-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.